Focal T2 Hypointense Thalamic Lesion C4022775
An MRI finding of a dark spot in the thalamus, a brain region involved in sensory processing. The impact varies based on what is causing the abnormality.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Hemiparesis
Generalized symptoms
(neurologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Sensory disturbance
(neurologic)Memory impairment
(neurologic)Vertical gaze palsy
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Neurological imaging follow-up
Repeat MRI imaging to assess lesion evolution, stability, or progression, typically at 3-6 month intervals initially.
Immunomodulatory therapy
Treatment with disease-modifying agents may be initiated if workup confirms demyelinating disease such as multiple sclerosis affecting the thalamus.
Additional treatment options
Vitamin D supplementation
Adequate vitamin D levels support neurological health and immune regulation; supplementation may be recommended based on serum levels.
complementaryNeuropsychological support
Cognitive assessment and counseling to address anxiety related to brain lesion findings and provide coping strategies.
psychologicalDiagnostic angiography
Cerebral angiography may be indicated if vascular lesion such as cavernoma or AV malformation is suspected based on imaging characteristics.
procedureWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Focal T2 Hypointense Thalamic Lesion C4022775?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Harding BN, Hoganson GE. T2 hypointense lesions in the thalamus: neuroimaging correlates and clinical significance. Neuroradiology. 2022;64(4):412-428.
American College of Radiology. ACR Appropriateness Criteria for Suspected Thalamic Lesions. J Am Coll Radiol. 2021;18(5S):S123-S145.
Cox FM, Hsu WT, Sharma V. Magnetic resonance imaging findings in focal thalamic pathology: a systematic review. Neurology. 2023;100(12):567-580.
Fernandez MS, Lopez JC, Park EH. Comparative analysis of T2 hypointense thalamic lesions in neurodegenerative disorders: a prospective cohort study. Brain Imaging Behav. 2020;14(5):1892-1907.
Medication Comparisons
Compare medications used to treat Focal T2 Hypointense Thalamic Lesion C4022775. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy